Merck stock holds steady as Trump drug pricing deal highlights sacituzumab program
Published on 09/01/2026 at 07:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co., Inc. (US58933Y1055) stock is trading slightly below $148 per share as of August 31, 2026, while investors weigh fresh political attention on its oncology pipeline and the latest second-quarter revenue mix. Per market data from the prior New York session, the shares were quoted around $147.83 intraday, modestly below a session high near $148.35, indicating a relatively stable performance heading into September 1, 2026. This price context intersects with renewed focus on Merck's antibody-drug conjugate sacituzumab tirumotecan in a recently discussed U.S. drug pricing framework, alongside resilient growth in cornerstone products such as Keytruda, Winrevair, and Welireg in the second quarter of 2026.
Stock trades below recent session high
Recent quote data from the New York trading session on August 31, 2026, show Merck shares changing hands at $147.76 late in the evening after opening at $147.00 earlier that day, reflecting a modest decline of roughly 0.4% from the opening level. In intraday trading, the stock dipped to a low of $146.06 before stabilizing back toward the high-$147 range, illustrating contained volatility despite sector-wide headlines on healthcare and drug pricing. Complementary market coverage noted that the stock was quoted around $147.83 at 4:28 p.m. ET, close to a reported session high near $148.35, placing the shares slightly below that high but well above the intraday low, a pattern that suggests investors are comfortable with the current valuation band for now.
Additional quote commentary for August 31, 2026, pointed to a prior reference price of $148.30 for Merck shares on the New York Stock Exchange, broadly consistent with the $147.76 to $147.83 range described later in the session. That context implies a marginal softening from that earlier level but without a pronounced break in trend, as the stock remains clustered around the mid-$140s to high-$140s zone rather than testing new 52-week extremes. For investors comparing intraday levels, the roughly $2.29 spread between the intraday low of $146.06 and the session high near $148.35 underscores a narrow trading corridor relative to many higher-beta peers, highlighting Merck's traditionally defensive profile within healthcare.
Pipeline spotlight in Trump drug pricing deal
A new healthcare-policy development on September 1, 2026, has added qualitative context for Merck's pipeline, with a U.S. drug pricing agreement expanding coverage across nine mid-sized pharmaceutical firms and highlighting several therapies for chronic and rare diseases. According to a live-market news brief on that day, the agreement ties certain outpatient drug prices in state Medicaid programs to overseas reference levels, particularly across treatments for conditions such as hemophilia and cancer. Within that broader narrative, an additional commentary piece on healthcare stocks noted that Merck's antibody-drug conjugate sacituzumab tirumotecan was singled out as part of the growth story underpinning recent gains in the sector, signaling that policymakers and market observers consider the program a meaningful asset in the company's oncology portfolio.
While the pricing deal itself appears to focus primarily on discount structures and alignment with overseas charging levels rather than singling out Merck's existing blockbuster drugs, the mention of sacituzumab tirumotecan in a healthcare-stocks overview reinforces investor interest in Merck's next-generation oncology pipeline beyond Keytruda. The news context, dated September 1, 2026, aligns with a broader narrative in which large-cap drug manufacturers balance pricing scrutiny with high-investment oncology programs, suggesting that Merck's exposure to advanced antibody-drug conjugates could remain an important valuation factor as U.S. policymakers continue to revisit the mechanics of Medicaid reimbursement.
Q2 2026 figures show revenue mix shifts
Recent second-quarter 2026 coverage of Merck's results provides a more detailed view of how individual drugs contribute to the company's top line. A healthcare-article summary described Merck's Keytruda therapy as one of the world's top-selling oncology products and noted that the drug accounted for 50% of the firm's $16.6 billion in second-quarter 2026 revenue, implying that Keytruda generated roughly $8.3 billion of that total in the period. In addition, Keytruda sales were reported to have increased 5% year over year in the second quarter, a pace that underscores continued growth even for a mature flagship product, and reinforces why the therapy remains central to Merck's investment narrative.
The same second-quarter 2026 overview highlighted strong expansion across other specialty therapies, particularly in rare-disease and cardiovascular segments. It indicated that sales of Merck's arterial hypertension treatment Winrevair rose 75% compared with the second quarter of the prior year, reaching $588 million in Q2 2026. In parallel, Welireg's revenue advanced 67% year over year to $271 million in the same quarter. The magnitude of these growth rates shows how certain newer or niche products are scaling quickly, helping diversify Merck's revenue mix so that Keytruda's 50% share of the $16.6 billion quarterly total does not crowd out contributions from other growth engines.
However, the second-quarter 2026 snapshot also emphasized that Merck posted a net loss in the quarter while facing intensified generic competition that was quantified at $2.5 billion in headwinds during 2026. That combination of strong product-level growth and pressure from generic erosion illustrates a nuanced profitability picture: select franchises like Winrevair and Welireg are producing double-digit revenue increases, yet the overall earnings profile is challenged by off-patent exposures and the costs associated with maintaining a broad pipeline. For investors, the interplay between these gains and headwinds is critical, as it helps frame whether Merck's net loss in Q2 2026 reflects transient factors or signals a more structural margin squeeze.
Analyst consensus and valuation signals
From the perspective of third-party coverage, Merck's equity story is also shaped by how market participants interpret the recent mix of strong product growth, net quarterly loss, and political scrutiny of drug pricing. A consensus overview compiled around August 31, 2026, indicated that a group of investment analysts maintain a positive stance on the stock, assigning Merck an overall rating in the buy band rather than a bearish designation. That same snapshot reported an average price target of $147.60 for Merck shares, placing the consensus valuation extremely close to the late-August trading levels around $147.76 to $148.35 and suggesting that, on average, sell-side models see limited near-term upside or downside relative to the current quote.
For investors comparing the consensus target with the observed price range, the difference of less than $1 between the average target of $147.60 and the intraday high near $148.35 on August 31, 2026, implies that Merck is trading almost exactly in line with this benchmark valuation. That alignment can be interpreted in two ways: either the stock has already priced in much of the positive news flow from growing oncology and rare-disease franchises, or analysts may revise their targets if upcoming quarters show that strong product growth is sustainably offsetting generic headwinds and policy uncertainty. In any case, the tight band between target and market price underscores that Merck is not currently viewed as deeply discounted or dramatically overvalued based on prevailing models.
Keytruda anchors Merck's oncology franchise
Within Merck's product lineup, the oncology immunotherapy Keytruda remains the flagship franchise and a central driver of long-term cash flows. As described in the second-quarter 2026 revenue overview, Keytruda delivered half of the company's $16.6 billion revenue in that period, pointing to a scale that few competing immunotherapies have matched. The 5% year-over-year growth in Keytruda sales during Q2 2026, despite the therapy's maturity and wide adoption, suggests ongoing expansion into new indications and geographies, as well as durable demand in existing treatment settings. That performance reinforces why Keytruda is often cited as one of the world's leading cancer treatments.
Looking beyond the headline revenue figure, Keytruda's role as a cash generator helps support Merck's investment in other oncology programs such as antibody-drug conjugates, along with therapies in cardiovascular and rare diseases. The fact that Winrevair and Welireg achieved year-over-year sales increases of 75% and 67%, respectively, in Q2 2026 while still contributing a combined $859 million in the quarter, underscores that Merck is building layered revenue streams across multiple therapeutic categories. This diversification can be particularly important as policymakers continue to examine pricing structures for high-cost oncology drugs, because it provides Merck with potential levers outside of Keytruda to sustain growth.
Shares on NYSE and latest price context
Merck & Co., Inc. shares trade on the New York Stock Exchange under the ticker MRK, making the stock a core component of major U.S. healthcare indices and a widely held position among institutional and retail investors. Based on the New York trading session on August 31, 2026, the stock closed near $147.76 after touching a low of $146.06 and an intraday high around $148.35, with intraday coverage citing a quote of $147.83 at roughly 4:28 p.m. ET. As of that date, the price level sits almost exactly in line with the consensus target of $147.60, which provides a useful reference point for investors evaluating Merck's short-term risk-reward profile.
Read more
Further details on Merck's share performance and analyst consensus, including recent commentary on oncology and cardiovascular franchises in the second quarter of 2026, can be found in an equity-research news summary dated August 31, 2026, which outlines product-level growth rates, the reported net loss, and the scale of generic headwinds in 2026.
Keytruda as a representative product
Keytruda, Merck's flagship immune checkpoint inhibitor, is a monoclonal antibody therapy that targets the PD-1 pathway to help the immune system recognize and attack cancer cells. The second-quarter 2026 coverage described Keytruda as one of the top-selling oncology therapies globally and quantified its revenue contribution at 50% of Merck's $16.6 billion total revenue for that quarter, translating into roughly $8.3 billion of sales over three months. The 5% year-over-year growth figure cited for Keytruda in Q2 2026 indicates that demand continues to expand, likely driven by new approvals and indications across cancers such as lung, melanoma, and head and neck, where immune checkpoint inhibition has become a standard-of-care component.
Closing price and investor view
Based on the latest completed New York session on August 31, 2026, Merck stock finished the day at $147.76, within a trading range that extended from an intraday low of $146.06 to a high point near $148.35. With the shares trading almost precisely in line with an average analyst target of $147.60 and supported by robust second-quarter growth in Keytruda, Winrevair, and Welireg despite a reported net loss and $2.5 billion in generic headwinds in 2026, Merck presents a profile in which product momentum and policy risk are tightly interwoven. Investors monitoring the stock around the start of September 2026 are likely to focus on whether future quarters confirm that expanding specialty-drug revenues can offset ongoing pressure from generics and evolving U.S. pricing frameworks.
Fact box
Company: Merck & Co., Inc.
ISIN: US58933Y1055
Ticker: MRK
Exchange: New York Stock Exchange (NYSE)
Price (as of August 31, 2026, 4:28 p.m. ET): $147.83 USD
Sector / Industry: Health Care / Pharmaceuticals
Index membership: S&P 500
